Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis

This study aimed to assess the evaluation of clinical outcomes and consequences of complications after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the peritoneal carcinomatosis (PC) from colorectal cancer. A total 26 patients underwent CRS and HIPEC for PC f...

Full description

Saved in:
Bibliographic Details
Published in:Annals of coloproctology 2020, 36(1), , pp.22-29
Main Authors: Roh, Seung Jae, Park, Sung Chan, Choi, Jaehee, Lee, Joon Sang, Lee, Dong Woon, Hong, Chang Won, Han, Kyung Su, Park, Hyoung Chul, Sohn, Dae Kyung, Oh, Jae Hwan
Format: Article
Language:English
Subjects:
colorectal neoplasms
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
Original
peritoneal carcinomatosis
일반외과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to assess the evaluation of clinical outcomes and consequences of complications after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the peritoneal carcinomatosis (PC) from colorectal cancer. A total 26 patients underwent CRS and HIPEC for PC from colorectal cancer between March 2009 and April 2018. All the patients underwent CRS with the purpose of complete or near-complete cytoreduction. Intraoperative HIPEC was performed simultaneously after the CRS. Mitomycin C was used as chemotherapeutic agent for HIPEC. Median disease-free survival was 27.8 months (range, 13.4-42.2 months). Median overall survival was 56.0 months (range, 28.6-83.5 months). The mean peritoneal cancer index (PCI) was 8.73 ± 5.54. The distributions thereof were as follows: PCI
ISSN:2287-9714
2287-9722
DOI:10.3393/ac.2019.04.30